Chief Financial Officer
Jill Anderson became our Chief Financial Officer on 1 August 2018.
Jill joined the ViiV Executive Team from GSK where she was VP Franchise Finance, Global Pharmaceutical and brings more than 25 years of experience working in the industry. She has held a broad range of roles of increasing responsibility across Finance, Commercial, R&D and Manufacturing. In her most recent role, Jill was accountable for leading the finance partnering on global commercial strategy, R&D financial investment appraisal, long range sales planning and profit optimisation across the portfolio lifecycle.
At the beginning of her career, Jill received her accounting qualification at Shell International Petroleum Company. She holds a degree in Chemistry from the University of Exeter, has been a school governor and is an active sponsor of the Accelerating Difference diversity programme in GSK.
Our Executive Team
YOU MAY ALSO BE INTERESTED IN
Together we are engaged in the HIV response throughout the world, supported by a team of over 1,100 dedicated ViiV Healthcare staff working across the globe.
Discover more about who we are, the work we do and what we're doing to advance HIV science, support the delivery of HIV treatment and care; and work with partners to address the stigma and discrimination faced by people living with HIV.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.